ACC 2015: Amgen, Regeneron/Sanofi make case for PCSK9 inhibitor safety
This article was originally published in Scrip
Amgen and its competitor Regeneron Pharmaceuticals with partner Sanofi won't report data from large-scale cardiovascular outcomes studies for their PCSK9 inhibitors until 2017, but the companies are sharing longer-term data from smaller clinical trials for their cholesterol-lowering therapies in hopes of encouraging prescriptions of the injectable drugs following US FDA approval later this year.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.